EMA Authorised: Beyonttra (acoramidis hydrochloride) — Bayer AG

View source ↗

Summary

The European Medicines Agency authorised Beyonttra (acoramidis hydrochloride) by Bayer AG for hereditary transthyretin-mediated amyloidosis with polyneuropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy

Drugs mentioned

• Beyonttra (acoramidis hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Amyloid Neuropathies, Familial. MAH: Bayer AG. Decision date: 03/11/2025